163 related articles for article (PubMed ID: 28427435)
1. Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways.
El-Etreby NM; Ghazy AA; Rashad R
J Ovarian Res; 2017 Apr; 10(1):28. PubMed ID: 28427435
[TBL] [Abstract][Full Text] [Related]
2. Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer.
Lu JJ; Zheng Y; Kang X; Yuan JM; Lauchlan SC; Pike MC; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):158-68. PubMed ID: 11063638
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory role of prohibitin in human ovarian epithelial cancer.
Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
5. Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation.
Cui J; Miner BM; Eldredge JB; Warrenfeltz SW; Dam P; Xu Y; Puett D
BMC Cancer; 2011 Jun; 11():280. PubMed ID: 21711548
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of p-AKT, p-GSK3β and β-catenin in epithelial carcinoma of ovary].
Wei X; Lü QJ; Sun HX; Qi YF; Wang JO; Cao CC
Zhonghua Bing Li Xue Za Zhi; 2012 Feb; 41(2):86-90. PubMed ID: 22455883
[TBL] [Abstract][Full Text] [Related]
7. [Expression of folate receptor alpha in ovarian epithelial tumors].
Shen DH; Xie JL; Zhang YL; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
[TBL] [Abstract][Full Text] [Related]
8. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
Feng QL; Shi HR; Qiao LJ; Zhao J
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
[TBL] [Abstract][Full Text] [Related]
9. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.
Song JY; Chen KY; Kim SY; Kim MR; Ryu KS; Cha JH; Kang CS; MacLaughlin DT; Kim JH
Int J Oncol; 2009 Jun; 34(6):1583-91. PubMed ID: 19424576
[TBL] [Abstract][Full Text] [Related]
10. Prohibitin as a novel target protein of luteinizing hormone in ovarian epithelial carcinogenesis.
Jia L; Yi XF; Zhang ZB; Zhuang ZP; Li J; Chambers SK; Kong BH; Zheng W
Neoplasma; 2011; 58(2):104-9. PubMed ID: 21275458
[TBL] [Abstract][Full Text] [Related]
11. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
Chudecka-Głaz A; Rzepka-Górska I; Kosmowska B
Arch Gynecol Obstet; 2004 Nov; 270(3):151-6. PubMed ID: 12883823
[TBL] [Abstract][Full Text] [Related]
13. [Survivin expression in ovarian carcinoma].
Yin RT; Peng ZL; Yang KX; Kang DY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):215-7, 233. PubMed ID: 16608078
[TBL] [Abstract][Full Text] [Related]
14. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
15. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
16. TGF-beta induces serous borderline ovarian tumor cell invasion by activating EMT but triggers apoptosis in low-grade serous ovarian carcinoma cells.
Cheng JC; Auersperg N; Leung PC
PLoS One; 2012; 7(8):e42436. PubMed ID: 22905131
[TBL] [Abstract][Full Text] [Related]
17. Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors.
Inan S; Vatansever S; Celik-Ozenci C; Sanci M; Dicle N; Demir R
Histol Histopathol; 2006 Oct; 21(10):1055-64. PubMed ID: 16835828
[TBL] [Abstract][Full Text] [Related]
18. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma.
Bristow RE; Baldwin RL; Yamada SD; Korc M; Karlan BY
Cancer; 1999 Feb; 85(3):658-68. PubMed ID: 10091739
[TBL] [Abstract][Full Text] [Related]
20. [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
Zhang J; Chen AP; Wang B; Zhao SP; Liu LZ; Dai SZ
Ai Zheng; 2008 Dec; 27(12):1331-6. PubMed ID: 19080004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]